Skip to content

In the BioHarmony Drug Report Database

Rimegepant

Nurtec Odt (rimegepant) is a small molecule pharmaceutical. Rimegepant was first approved as Nurtec Odt on 2020-02-27. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. The pharmaceutical is active against calcitonin gene-related peptide type 1 receptor. Nurtec odt's patents are valid until 2039-03-25 (FDA).
Trade Name Nurtec Odt
Common Name Rimegepant
Indication migraine disorders, migraine with aura, migraine without aura
Drug Class Calcitonin gene-related peptide receptor antagonists
Rimegepant
Get full access now